GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
07 déc. 2020 07h00 HE
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
01 déc. 2020 08h30 HE
|
GW Pharmaceuticals plc
- Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in...
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference
30 nov. 2020 07h32 HE
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
13 nov. 2020 08h30 HE
|
GW Pharmaceuticals plc
- Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this...
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
09 nov. 2020 07h30 HE
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress
03 nov. 2020 07h30 HE
|
GW Pharmaceuticals plc
- Total revenue increased 51 percent to $137.1 million – - Epidiolex for seizures associated with TSC launched in the U.S. -- Nabiximols Phase 3 program in MS spasticity now recruiting -- Conference...
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
03 nov. 2020 07h15 HE
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020
22 oct. 2020 10h34 HE
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community
21 oct. 2020 08h00 HE
|
GW Pharmaceuticals plc
-- Technology provides a new way for the community to communicate and connect -- -- Launching in collaboration with patient advocacy organizations, this web-based, image-recognition technology...
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
23 sept. 2020 03h54 HE
|
GW Pharmaceuticals plc
LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved...